IP Verse

Enterically Coated Cysteamine, Cystamine And Derivatives Thereof - EP2535044

EP2535044

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Application Number
EP12169866A
Filing Date
Jan 26, 2007
Status
Revoked
Apr 27, 2024
Grant Date
Dec 18, 2019
External Links
Slate, Register, Google Patents

Bibliography

The patent EP2535044B1 was granted to The Regents OF The University OF California on Dec 18, 2019 following the initial filing on Jan 26, 2007 under the application number EP12169866A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHERSep 18, 2020ADMISSIBLE

Patent Citations New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePatent NumberPatent Link
DESCRIPTIONUS2809918
DESCRIPTIONUS3835221
DESCRIPTIONUS4301146
DESCRIPTIONUS4432966
DESCRIPTIONUS4728512
DESCRIPTIONUS4794001
DESCRIPTIONUS5225202
SEARCHUS2005245433
SEARCHWO03070020
SEARCHWO2005063226

Non-Patent Literature (NPL) Citations New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- F. W. GOODHART ET AL., PHARM. TECH., (198404), pages 64 - 71-
DESCRIPTION- NATURE MEDICINE, (2002), vol. 8, pages 143 - 149-
OPPOSITION- "2.2 Resorption", Mutschler E. et al, Mutschler Arzneimittelwirkungen - Lehrbuch der Pharmakologie und Toxikologie, Stuttgart, Wissenschaftliche Verlagsgesellschaft, (20010000), pages 9 - 15, ISBN 978-3-8047-1763-2, XP055741473-
OPPOSITION- Schneider J. A. et al, "Recent advances in the treatment of cystinosis", J. Inher. Metab. Dis., (19950000), vol. 18, no. 4, pages 387 - 397, XP055741470
OPPOSITION- Dohil R et alanjan, "Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis", Pediatr. Nephrol., (20051201), vol. 20, no. 12, pages 1786 - 1793, XP019347688
OPPOSITION- Levtchenko Elena N. et al, "Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis", Pediatric Nephrology, (20061001), vol. 21, no. 1, pages 110 - 113, XP019347994
OPPOSITION- Schneider Jerry A., "Treatment of cystinosis: Simple in principle, difficult in practice", The Journal of Pediatrics, (20041001), vol. 145, no. 4, pages 436 - 438, XP004596562
OPPOSITION- Belldina Eric B. et al, "Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients : Pharmacokinetics of cysteamine", Br. J. Clin. Pharmacol., (20031100), vol. 56, no. 5, pages 520 - 525, XP055741466
OPPOSITION- Gahl William A. et al, "Cystinosis", The New England Journal of Medicine, (20020711), vol. 347, no. 2, pages 111 - 121, XP055741477
OPPOSITION- Dohil Ranjan et al, "The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine", J. Pediatr., (20030801), vol. 143, no. 2, pages 224 - 230, XP009132048
OPPOSITION- Thoene J G et al, "Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo", The Journal of Clinical Investigation, (19760701), vol. 58, no. 1, pages 180 - 189, XP008046077
OTHER- Berwyn Owen, "Formulation and processing of cysteamine hydrochloride gastro-resistant pellets for the treatment of cystinosis", Thesis University of Sunderland, (20000200), XP055545133-
SEARCH- WANG X ET AL, "Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 231, no. 1-2, ISSN 0022-510X, (20050415), pages 57 - 66, (20050415), XP027713071 [I] 1-11 * the whole document *-
SEARCH- ELENA N LEVTCHENKO ET AL, "Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis", PEDIATRIC NEPHROLOGY ; JOURNAL OF THE INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION, SPRINGER, BERLIN, DE, (20060101), vol. 21, no. 1, doi:10.1007/S00467-005-2052-0, ISSN 1432-198X, pages 110 - 113, XP019347994 [I] 1-11 * the whole document *
SEARCH- THOENE J G ET AL, "CYSTINOSIS INTRACELLULAR CYSTINE DEPLETION BY AMINOTHIOLS IN VITRO AND IN VIVO", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (19760701), vol. 58, no. 1, doi:10.1172/JCI108448, ISSN 0021-9738, pages 180 - 189, XP008046077 [I] 1-11 * the whole document *
SEARCH- BUTLER DEB J ET AL, "PANTETHINE AND CYSTAMINE DEPLETE CYSTINE FROM CYSTINOTIC FIBROBLASTS VIA EFFLUX OF CYSTEAMINE-CYSTEINE MIXED DISULFIDE", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US LNKD- DOI:10.1172/JCI111436, (19840801), vol. 74, ISSN 0021-9738, pages 411 - 416, XP008025848 [I] 1-11 * abstract * * page 415, paragraph Discussion *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents